The first-in-human trial, ELU-FRα-1, is currently under clincal trail in studies on, among others, ovarian cancer patients overexpressing FRα and topoisomerase 1 inhibitor-sensitive, NCT05001282 [94]. Here, FOLR1 is linked to ovarian carcinoma.